Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Synnøve YndestadChristina EngebrethsenAndrea Herencia-RoperoOleksii NikolaienkoOlav K VintermyrReidun K LillestølLaura MinsaasBeryl LeirvaagGjertrud T IversenBjørnar GiljeEgil S BlixHelge EspelidSteinar LundgrenJürgen GeislerHildegunn S AaseTurid AasEinar G GudlaugssonAlba Llop-GuevaraVioleta SerraEmilius A M JanssenPer Eystein LønningStian KnappskogHans Petter EikesdalPublished in: JCO precision oncology (2023)
The prevalence of HRD in non-TNBC suggests that therapy targeting HRD should be evaluated in a wider breast cancer patient population. Strict HRD criteria should be implemented to increase diagnostic precision with respect to functional HRD.